Piper Sandler analyst David Westenberg lowered the firm’s price target on Cytek Biosciences to $10 from $11 and keeps an Overweight rating on the shares. The firm cites the company’s earnings results.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CTKB:
- Cytek Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Outlook
- Cytek Biosciences sees FY24 revenue $203M-$213M, consensus $207.1M
- Cytek Biosciences reports Q4 adjusted EBITDA $11.0M vs. $6.6M last year
- Cytek Biosciences Enhances Executive Severance Benefit Plan
- Cytek Biosciences to Participate in Upcoming Investor Conferences
